GLAB.F Stock Overview
A biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Gemina Laboratories Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.63 |
| 52 Week High | CA$0.63 |
| 52 Week Low | CA$0.23 |
| Beta | 0.095 |
| 11 Month Change | 163.27% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 49.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| GLAB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 68.8% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how GLAB.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GLAB.F performed against the US Market.
Price Volatility
| GLAB.F volatility | |
|---|---|
| GLAB.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GLAB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GLAB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Brian Firth | www.geminalabs.com |
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It is developing respiratory syncytial virus and tuberculosis.
Gemina Laboratories Ltd. Fundamentals Summary
| GLAB.F fundamental statistics | |
|---|---|
| Market cap | US$48.02m |
| Earnings (TTM) | -US$2.66m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-18.0x
P/E RatioIs GLAB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAB.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.72m |
| Earnings | -CA$3.72m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.05 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -42.1% |
How did GLAB.F perform over the long term?
See historical performance and comparison